146 related articles for article (PubMed ID: 24385807)
1. Prognostic Significance of Bcl-2 and p53 Protein Expressions and Ki67 Proliferative Index in Diffuse Large B-cell Lymphoma.
Küçükzeybek BB; Bener S; Çallı AO; Paksoy TD; Payzin B
Turk J Haematol; 2013 Sep; 30(3):275-82. PubMed ID: 24385807
[TBL] [Abstract][Full Text] [Related]
2. [Ki-67 proliferative index in non-Hodgkin's lymphoma and its clinical significance].
Li J; Hu R; Liao AJ; Shi HY; Yan W; Liu ZG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):935-9. PubMed ID: 21867618
[TBL] [Abstract][Full Text] [Related]
3. The prognostic role of Bcl-2, Ki67, c-MYC and p53 in diffuse large B-cell lymphoma.
Pătraşcu AM; Rotaru I; Olar L; Pătraşcu Ş; Ghiluşi MC; NeamŢu SD; Nacea JG; Gluhovschi A
Rom J Morphol Embryol; 2017; 58(3):837-843. PubMed ID: 29250662
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of bcl-2 and p53 oncoproteins: correlation with Ki67 proliferation index and prognostic histopathologic parameters in colorectal neoplasia.
Saleh HA; Jackson H; Banerjee M
Appl Immunohistochem Mol Morphol; 2000 Sep; 8(3):175-82. PubMed ID: 10981868
[TBL] [Abstract][Full Text] [Related]
5. Ki67 Proliferation Index in Germinal and Non-Germinal Subtypes of Diffuse Large B-Cell Lymphoma.
Hashmi AA; Iftikhar SN; Nargus G; Ahmed O; Asghar IA; Shirazi UA; Afzal A; Irfan M; Ali J
Cureus; 2021 Feb; 13(2):e13120. PubMed ID: 33728138
[TBL] [Abstract][Full Text] [Related]
6. [Effect of Different Protein Expression and Clinical Features on the Prognosis of Patients with Diffuse Large B-Cell Lymphoma].
Cheng FF; Chen JF; Yang LH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1490-1496. PubMed ID: 31607303
[TBL] [Abstract][Full Text] [Related]
7. Systemic immune inflammation index, ratio of lymphocytes to monocytes, lactate dehydrogenase and prognosis of diffuse large B-cell lymphoma patients.
Wu XB; Hou SL; Liu H
World J Clin Cases; 2021 Nov; 9(32):9825-9834. PubMed ID: 34877321
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma.
Llanos M; Alvarez-Argüelles H; Alemán R; Oramas J; Diaz-Flores L; Batista N
Med Oncol; 2001; 18(1):15-22. PubMed ID: 11778965
[TBL] [Abstract][Full Text] [Related]
9. Expression of P63 and its correlation with prognosis in diffuse large B-cell lymphoma: a single center experience.
Hu WM; Jin JT; Wu CY; Lu JB; Zhang LH; Zeng J; Lin SX
Diagn Pathol; 2019 Nov; 14(1):128. PubMed ID: 31711519
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical investigation of P16, P53 and Ki-67's prognostic values in diffuse large B-Cell lymphomas.
Baran M; Canoz O; Altuntas H; Sivgin S; Cetin M; Yay A; Ketenci S
Bratisl Lek Listy; 2017; 118(10):602-608. PubMed ID: 29198127
[TBL] [Abstract][Full Text] [Related]
11. Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals.
Chang CC; Kampalath B; Schultz C; Bunyi-Teopengco E; Logan B; Eshoa C; Dincer AP; Perkins SL
Arch Pathol Lab Med; 2003 Feb; 127(2):208-12. PubMed ID: 12562237
[TBL] [Abstract][Full Text] [Related]
12. [Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma].
Yao WK; Wang YP; Peng F; Zheng Y; Zou YB; Gao JN; Liu XL
Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):818-22. PubMed ID: 23324230
[TBL] [Abstract][Full Text] [Related]
13. Bcl-6 expression and lactate dehydrogenase level predict prognosis of primary gastric diffuse large B-cell lymphoma.
Chung KM; Chang ST; Huang WT; Lu CL; Wu HC; Hwang WS; Chang KY; Chuang SS
J Formos Med Assoc; 2013 Jul; 112(7):382-9. PubMed ID: 23927977
[TBL] [Abstract][Full Text] [Related]
14. Poor outcome in patients with diffuse large B-cell lymphoma is associated with high percentage of bcl-2 and Ki 67-positive tumor cells.
Jovanović MP; Jaković L; Bogdanović A; Marković O; Martinović VC; Mihaljević B
Vojnosanit Pregl; 2009 Sep; 66(9):738-43. PubMed ID: 19877554
[TBL] [Abstract][Full Text] [Related]
15. Prognostic clinicopathologic factors, including immunologic expression in diffuse large B-cell lymphomas.
Zhang A; Ohshima K; Sato K; Kanda M; Suzumiya J; Shimazaki K; Kawasaki C; Kikuchi M
Pathol Int; 1999 Dec; 49(12):1043-52. PubMed ID: 10632924
[TBL] [Abstract][Full Text] [Related]
16. Primary gastrointestinal B-cell lymphoma. A clincopathological and immunohistochemical study of 61 cases with an evaluation of prognostic parameters.
Krugmann J; Dirnhofer S; Gschwendtner A; Berresheim U; Greil R; Krugmann K; Fend F
Pathol Res Pract; 2001; 197(6):385-93. PubMed ID: 11432665
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma.
Colomo L; López-Guillermo A; Perales M; Rives S; Martínez A; Bosch F; Colomer D; Falini B; Montserrat E; Campo E
Blood; 2003 Jan; 101(1):78-84. PubMed ID: 12393466
[TBL] [Abstract][Full Text] [Related]
18. Double-Expressor Phenotype (BCL-2/c-MYC Co-expression) of Diffuse Large B-Cell Lymphoma and Its Clinicopathological Correlation.
Hashmi AA; Iftikhar SN; Nargus G; Ahmed O; Asghar IA; Shirazi UA; Afzal A; Irfan M; Ali J
Cureus; 2021 Feb; 13(2):e13155. PubMed ID: 33692924
[TBL] [Abstract][Full Text] [Related]
19. The pretreatment albumin to globulin ratio as a significant predictor in patients with diffuse large B cell lymphoma.
Yue W; Liu B; Gao L; He M; Wang J; Zhang W; Chen L; Hu X; Xu L; Yang J
Clin Chim Acta; 2018 Oct; 485():316-322. PubMed ID: 30006285
[TBL] [Abstract][Full Text] [Related]
20. [Retrospective analysis of the clinical features and prognostic factors of 370 patients with advanced-stage diffuse large B-cell lymphoma].
Han Y; Qin Y; He XH; Yang JL; Liu P; Zhang CG; Zhou LQ; Zhou SY; Gui L; Song YW; Sun Y; Shi YK
Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):456-461. PubMed ID: 29936773
[No Abstract] [Full Text] [Related]
[Next] [New Search]